Novavax宣布监管机构批准更新的新冠疫苗

2026-08-28 21:25

Novavax (NVAX) on Friday announced that the U.S., European Union, and Japan have approved the updated versions of its COVID-19 vaccine Nuvaxovid, developed with partners Sanofi (ANY) and Takeda (TAK), globally.
The approval for the protein-based shot adjusted for the currently dominant SARS-CoV-2 XFG variant of COVID comes ahead of the 2026-2027 vaccination season in those major markets, the Maryland-area biotech said.
Under a 2024 partnership, Novavax (NVAX) is entitled to receive royalties from Sanofi (SNY), which leads commercial activities for Nuvaxovid in countries such as the U.S., Germany, and Canada.
Takeda (TAK), which commercializes Nuvaxovid in Japan, is also required to pay annual milestones linked to regulatory approvals and royalties on net sales of the vaccine.
Late Thursday, Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) also announced FDA approval of their messenger-RNA-based COVID-19 shots adjusted for XFG variant.

More on Novavax, Sanofi, etc.